YMAB FY2024 EPS Forecast Increased by Cantor Fitzgerald

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for Y-mAbs Therapeutics in a report released on Monday, November 11th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.66) per share for the year, up from their previous estimate of ($0.67). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same quarter in the prior year, the company earned ($0.18) EPS.

Several other equities research analysts also recently issued reports on YMAB. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Morgan Stanley lowered their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 13th. Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $11.59 on Thursday. The company has a fifty day moving average price of $14.03 and a two-hundred day moving average price of $13.12. Y-mAbs Therapeutics has a one year low of $5.04 and a one year high of $20.90. The stock has a market cap of $519.10 million, a P/E ratio of -21.46 and a beta of 0.68.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of institutional investors have recently added to or reduced their stakes in YMAB. Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after buying an additional 613,175 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at $44,000. FMR LLC boosted its holdings in shares of Y-mAbs Therapeutics by 23.1% during the 3rd quarter. FMR LLC now owns 36,416 shares of the company’s stock valued at $479,000 after acquiring an additional 6,822 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Y-mAbs Therapeutics by 9.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock worth $3,676,000 after acquiring an additional 23,982 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $133,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Joris Wilms sold 5,000 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at approximately $449,514. This represents a 14.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. The trade was a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 100,000 shares of company stock worth $1,338,100. 22.50% of the stock is currently owned by corporate insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.